Search

Displaying results 2831 - 2840 of 6076 in total
  1. Drug

    Gabexate

    go.drugbank.com/drugs/DB12831
    Investigational

    Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220]

  2. Drug

    XL844

    go.drugbank.com/drugs/DB05149
    Investigational

    XL844 is investigated for the use and treatment solid tumors. XL844 is a solid.

  3. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder ...

    Categories: Antidepressive Agents Indicated for Depression, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  4. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [L41315] Metreleptin was approved by Health Canada in January 2024 for the same patient population, in addition to patients with partial lipodystrophy.[L49901] … [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized

  5. Drug

    Melperone

    go.drugbank.com/drugs/DB09224
    Investigational

    Melperone has been used for a span of greater than 30 years in the European Union [L1316].

  6. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    [L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia. … Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase

  7. Drug

    Pegaptanib

    go.drugbank.com/drugs/DB04895
    ApprovedWithdrawn

    Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.

  8. Drug

    Trefoil Factor 2

    go.drugbank.com/drugs/DB15750
    Experimental

    They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells, although expression of TFF2 mRNA transcripts also occurs with tissue macrophages.

  9. Drug

    Oxyphencyclimine

    go.drugbank.com/drugs/DB00383
    Approved

    Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.

    Categories: Drugs for Functional Gastrointestinal Disorders
  10. Drug

    Boron

    go.drugbank.com/drugs/DB11203
    ApprovedInvestigational

    additive in glass fibers of boron-containing fiberglass for insulation and structural materials. … It is also found for applications including ceramics, high-hardness or abrasive compounds, metal coatings, detergents, bleaching agents, insecticides, semiconductors, magnets, wood preservatives, and an